- Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
- A moving average of short volume ratio is at a recent 2 week low. A lower short volume ratio could be a bullish signal.
- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. in Q2 2021 and in the EU in Mid-2021 – – Pivotal Trials for Mitapivat in Thalassemia on Track for Initiation in 2H 2021 and in Sickle Cell Disease by Year-End – – Sale of Oncology Portfolio to Servier Expected to Close in Q2 2021, Enabling Agios to Focus on Genetically Defined Diseases – – Company’s 2025 Strategic Vision Includes Commercialization of Mitap...
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. ET. A live webcast of the presentation and breakout session can be accessed under "Events & Presentations" in the Investors section of the company's ...
Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.
Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases. Shares rise.
Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.
Agios Pharmaceuticals will sell its oncology business to Servier for up to $2 billion, the biotech company said Monday. In response, AGIO stock skyrocketed by double digits.
Agios stock is soaring in Monday trading after announcing the sale of its cancer products. The company will focus on sickle cell and other rare inherited disorders.